CA3095078A1 - Full flow-through process for purifying recombinant proteins - Google Patents
Full flow-through process for purifying recombinant proteins Download PDFInfo
- Publication number
- CA3095078A1 CA3095078A1 CA3095078A CA3095078A CA3095078A1 CA 3095078 A1 CA3095078 A1 CA 3095078A1 CA 3095078 A CA3095078 A CA 3095078A CA 3095078 A CA3095078 A CA 3095078A CA 3095078 A1 CA3095078 A1 CA 3095078A1
- Authority
- CA
- Canada
- Prior art keywords
- membrane
- combination
- tris
- buffer
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 174
- 230000008569 process Effects 0.000 title description 40
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 4
- 239000012528 membrane Substances 0.000 claims abstract description 257
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 116
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 116
- 238000011026 diafiltration Methods 0.000 claims abstract description 53
- 239000002738 chelating agent Substances 0.000 claims abstract description 50
- 238000005498 polishing Methods 0.000 claims abstract description 41
- 238000001914 filtration Methods 0.000 claims abstract description 32
- 239000000872 buffer Substances 0.000 claims description 94
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 60
- 238000000746 purification Methods 0.000 claims description 51
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 239000011159 matrix material Substances 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 33
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 31
- 239000007983 Tris buffer Substances 0.000 claims description 30
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 30
- 239000012460 protein solution Substances 0.000 claims description 27
- 239000012465 retentate Substances 0.000 claims description 23
- 239000011347 resin Substances 0.000 claims description 20
- 229920005989 resin Polymers 0.000 claims description 20
- 230000003993 interaction Effects 0.000 claims description 17
- 239000006167 equilibration buffer Substances 0.000 claims description 16
- 230000007246 mechanism Effects 0.000 claims description 14
- -1 Tris-HCI Chemical compound 0.000 claims description 13
- 230000009471 action Effects 0.000 claims description 13
- 238000011210 chromatographic step Methods 0.000 claims description 13
- 238000001728 nano-filtration Methods 0.000 claims description 13
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000009295 crossflow filtration Methods 0.000 claims description 10
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 10
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 10
- 235000019800 disodium phosphate Nutrition 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 239000003957 anion exchange resin Substances 0.000 claims description 8
- 239000012510 hollow fiber Substances 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 8
- 238000010979 pH adjustment Methods 0.000 claims description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 8
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 238000012432 intermediate storage Methods 0.000 claims description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 109
- 239000013017 sartobind Substances 0.000 description 53
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 18
- 239000000356 contaminant Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 238000003860 storage Methods 0.000 description 11
- 230000002779 inactivation Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000011012 sanitization Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241000270276 Natrix Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000011437 continuous method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102100028496 Galactocerebrosidase Human genes 0.000 description 1
- 108010042681 Galactosylceramidase Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 102000016870 Hexosaminidase B Human genes 0.000 description 1
- 108010053345 Hexosaminidase B Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 108010053927 Iduronate Sulfatase Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108010044965 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase Proteins 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 229950004283 actoxumab Drugs 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229960003227 afelimomab Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 229950005122 atinumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229950001303 biciromab Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000013621 viresolve pro solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305338.8 | 2018-03-27 | ||
| EP18305338.8A EP3546475A1 (en) | 2018-03-27 | 2018-03-27 | Full flow-through process for purifying recombinant proteins |
| PCT/EP2019/057687 WO2019185691A1 (en) | 2018-03-27 | 2019-03-27 | Full flow-through process for purifying recombinant proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095078A1 true CA3095078A1 (en) | 2019-10-03 |
Family
ID=61972052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095078A Pending CA3095078A1 (en) | 2018-03-27 | 2019-03-27 | Full flow-through process for purifying recombinant proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210009634A1 (ko) |
| EP (2) | EP3546475A1 (ko) |
| JP (1) | JP7396997B2 (ko) |
| KR (1) | KR20200135371A (ko) |
| CN (1) | CN112189015A (ko) |
| AU (1) | AU2019246328A1 (ko) |
| BR (1) | BR112020019409A2 (ko) |
| CA (1) | CA3095078A1 (ko) |
| IL (1) | IL277544A (ko) |
| MX (1) | MX2020010077A (ko) |
| SG (1) | SG11202009193VA (ko) |
| TW (1) | TWI828671B (ko) |
| WO (1) | WO2019185691A1 (ko) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005100394A2 (en) * | 2004-04-14 | 2005-10-27 | F. Hoffmann-La Roche Ag | PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF |
| US20100190210A1 (en) * | 2006-03-20 | 2010-07-29 | Medarex, Inc. | Protein Purification |
| MX2011001506A (es) * | 2008-08-14 | 2011-03-15 | Genentech Inc | Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena. |
| US9284347B2 (en) * | 2010-01-22 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Chromatographic method for purifying FC-containing proteins |
| CN103379949B (zh) * | 2010-10-11 | 2016-09-14 | 艾伯维巴哈马有限公司 | 蛋白纯化方法 |
| US20120238730A1 (en) * | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
| CA2830640A1 (en) * | 2011-03-25 | 2012-10-04 | Genentech, Inc. | Novel protein purification methods |
| US8506797B2 (en) * | 2011-04-10 | 2013-08-13 | Therapeutic Proteins International, LLC | Downstream bioprocessing device |
| US9096648B2 (en) * | 2011-08-19 | 2015-08-04 | Emd Millipore Corporation | Methods of reducing level of one or more impurities in a sample during protein purification |
| WO2013075740A1 (en) * | 2011-11-23 | 2013-05-30 | Sanofi | Antibody purification method |
| CN104125963B (zh) * | 2011-12-22 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 使用离子交换膜层析改进下游蛋白质纯化步骤的方法 |
| SG10201701224UA (en) * | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
| DK2864346T3 (en) * | 2012-06-21 | 2019-02-04 | Synthon Biopharmaceuticals Bv | Method of purifying an antibody. |
| EP2682168A1 (en) * | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
| US9650411B2 (en) * | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
| MX2015012114A (es) | 2013-03-08 | 2016-01-12 | Genzyme Corp | Fabricacion continua integrada de principios activos proteinicos terapeuticos. |
| CN116003579A (zh) * | 2013-05-06 | 2023-04-25 | 赛诺菲 | 用于纯化抗体的连续多步骤方法 |
| KR101569783B1 (ko) * | 2013-06-05 | 2015-11-19 | 한화케미칼 주식회사 | 항체의 정제 방법 |
| JP2017507938A (ja) * | 2014-02-19 | 2017-03-23 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 分別法 |
| JP2017025025A (ja) * | 2015-07-23 | 2017-02-02 | 旭化成メディカル株式会社 | タンパク質の精製方法 |
| JP7032046B2 (ja) * | 2016-01-22 | 2022-03-08 | 旭化成メディカル株式会社 | 生理活性物質の連続的な定流速精製方法 |
| DK3484599T3 (da) * | 2016-07-13 | 2020-06-15 | Chromacon Ag | Oprensningsfremgangsmåde og anvendelser deraf |
| WO2018170488A1 (en) * | 2017-03-17 | 2018-09-20 | Gilead Sciences, Inc. | Method of purifying an antibody |
-
2018
- 2018-03-27 EP EP18305338.8A patent/EP3546475A1/en not_active Withdrawn
-
2019
- 2019-03-26 TW TW108110547A patent/TWI828671B/zh active
- 2019-03-27 MX MX2020010077A patent/MX2020010077A/es unknown
- 2019-03-27 KR KR1020207027705A patent/KR20200135371A/ko not_active Application Discontinuation
- 2019-03-27 SG SG11202009193VA patent/SG11202009193VA/en unknown
- 2019-03-27 JP JP2020551845A patent/JP7396997B2/ja active Active
- 2019-03-27 BR BR112020019409-3A patent/BR112020019409A2/pt unknown
- 2019-03-27 CN CN201980033968.5A patent/CN112189015A/zh active Pending
- 2019-03-27 WO PCT/EP2019/057687 patent/WO2019185691A1/en unknown
- 2019-03-27 EP EP19713037.0A patent/EP3774839A1/en active Pending
- 2019-03-27 US US17/040,702 patent/US20210009634A1/en active Pending
- 2019-03-27 AU AU2019246328A patent/AU2019246328A1/en active Pending
- 2019-03-27 CA CA3095078A patent/CA3095078A1/en active Pending
-
2020
- 2020-09-23 IL IL277544A patent/IL277544A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210009634A1 (en) | 2021-01-14 |
| IL277544A (en) | 2020-11-30 |
| SG11202009193VA (en) | 2020-10-29 |
| KR20200135371A (ko) | 2020-12-02 |
| MX2020010077A (es) | 2020-10-28 |
| CN112189015A (zh) | 2021-01-05 |
| TW201945385A (zh) | 2019-12-01 |
| WO2019185691A1 (en) | 2019-10-03 |
| EP3774839A1 (en) | 2021-02-17 |
| TWI828671B (zh) | 2024-01-11 |
| BR112020019409A2 (pt) | 2021-01-05 |
| RU2020131568A (ru) | 2022-04-27 |
| JP7396997B2 (ja) | 2023-12-12 |
| JP2021519303A (ja) | 2021-08-10 |
| AU2019246328A1 (en) | 2020-10-15 |
| EP3546475A1 (en) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102272851B1 (ko) | 항체를 정제하기 위한 연속 다단계 공정 | |
| AU2017245478B2 (en) | Protein purification using Bis-Tris buffer | |
| US20210009634A1 (en) | Full flow-through process for purifying recombinant proteins | |
| RU2792435C2 (ru) | Полностью проточный способ очистки рекомбинантных белков | |
| EP2782925B1 (en) | Protein purification using bis-tris buffer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220829 |
|
| EEER | Examination request |
Effective date: 20220829 |
|
| EEER | Examination request |
Effective date: 20220829 |
|
| EEER | Examination request |
Effective date: 20220829 |
|
| EEER | Examination request |
Effective date: 20220829 |
|
| EEER | Examination request |
Effective date: 20220829 |